Published in J Hepatol on April 01, 1998
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology (2009) 2.07
Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut (2004) 1.65
Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol (2005) 1.22
Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis (2004) 1.10
Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol (2007) 1.02
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut (2001) 1.00
Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol (2013) 0.92
Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. World J Gastroenterol (2011) 0.85
Current Treatment for Chronic Hepatitis C. Curr Treat Options Gastroenterol (2004) 0.80
Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance. Hepat Mon (2013) 0.79
Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. World J Hepatol (2013) 0.76
The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection. Int J Hepatol (2011) 0.75
Nonresponse to interferon monotherapy in HCV-related chronic hepatitis: results of retreatment and prognostic factors. Dig Dis Sci (2003) 0.75
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Health services: an Italian market. Lancet (1996) 3.43
Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut (2004) 3.26
The treatment of portal hypertension: a meta-analytic review. Hepatology (1995) 3.11
Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol (2001) 2.93
Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA (2000) 2.76
Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol (2001) 2.36
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2011) 2.34
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol (2011) 2.31
Smoking habits and recurrence in Crohn's disease. Gastroenterology (1994) 2.30
Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology (1997) 2.22
Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis (1999) 2.15
Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci (1991) 2.12
Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci (1986) 2.07
Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology (1999) 2.02
Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? Hepatology (2001) 1.99
Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2011) 1.95
Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med (1992) 1.92
Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol (1997) 1.85
Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology (1998) 1.74
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol (1998) 1.74
Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Aliment Pharmacol Ther (2011) 1.73
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther (2011) 1.73
Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis (2007) 1.73
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
The long-term course of chronic hepatitis B. Hepatology (1999) 1.63
Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease. Gastroenterology (1991) 1.62
Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials. Am J Gastroenterol (1999) 1.60
Successful control of an outbreak of colonization by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae sequence type 258 in a neonatal intensive care unit, Italy. J Hosp Infect (2013) 1.59
Natural history of chronic hepatitis C. Ital J Gastroenterol Hepatol (1999) 1.59
Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis (2009) 1.58
Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther (2011) 1.58
Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res (2001) 1.57
Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology (1995) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Hepatitis C virus replication in 'autoimmune' chronic hepatitis. J Hepatol (1991) 1.52
Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther (2011) 1.51
Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis. J Viral Hepat (2013) 1.51
Ongoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital, Italy, June to December 2011. Euro Surveill (2012) 1.50
Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic cirrhotic patients. Hepatology (1983) 1.49
Natural occurrence of scrapie in goats in Italy. Vet Rec (1998) 1.49
Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes. Cancer (1999) 1.43
TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. Radiology (1999) 1.42
Ultrasound changes in abdominal echinococcosis treated with albendazole. J Clin Ultrasound (1991) 1.42
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. Hepatol Int (2014) 1.41
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol (1994) 1.40
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol (1991) 1.40
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis (2006) 1.34
The molecular nature of the F-actin binding activity of aldolase revealed with site-directed mutants. J Biol Chem (1996) 1.32
Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther (1999) 1.28
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
Spinal disorders at the cervicothoracic junction. Spine (Phila Pa 1976) (1994) 1.27
Structure and growth-dependent regulation of the human cyclin B1 promoter. Exp Cell Res (1995) 1.26
Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci (2010) 1.24
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Distribution of VP7 serotypes and VP4 genotypes among rotavirus strains recovered from Italian children with diarrhea. Arch Virol (1997) 1.23
Glucose tolerance is negatively associated with circulating progenitor cell levels. Diabetologia (2007) 1.21
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Search for dark matter candidates and large extra dimensions in events with a photon and missing transverse momentum in pp collision data at sqrt[s]=7 TeV with the ATLAS detector. Phys Rev Lett (2013) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Liver transplantation: the Italian experience. Dig Liver Dis (2002) 1.19
Hepatitis C virus and Sjögren's syndrome. Lancet (1992) 1.19
Mortality and causes of death in celiac disease in a Mediterranean area. Dig Dis Sci (1999) 1.16
Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res (2012) 1.14
Distal spleno-renal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. A meta-analysis of 4 randomized clinical trials. J Hepatol (1992) 1.14
Search for a supersymmetric partner to the top quark in final states with jets and missing transverse momentum at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.13
Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. Hepatology (1994) 1.12
Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer (1985) 1.12
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther (2008) 1.12
Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial. Dig Dis Sci (1983) 1.12